BeyondSpring (BYSI) Net Income towards Common Stockholders (2016 - 2026)
BeyondSpring (BYSI) posted Net Income towards Common Stockholders of -$2.2 million for Q1 2026, up 34.26% sequentially from -$3.3 million in Q4 2025, and down 148.22% YoY from $4.5 million in Q1 2025.
BeyondSpring (BYSI) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
BeyondSpring has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$2.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 148.22% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (down 94.88% YoY) and the FY2025 annual result came in at -$12.5 million, down 59.53% from the prior year.
- Net Income towards Common Stockholders climbed to -$2.2 million in Q1 2026 per BYSI's latest filing, from -$3.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $4.5 million in Q1 2025 and troughed at -$4.0 million in Q2 2024.
- A 3-year average of -$1.8 million and a median of -$2.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders soared 238.56% in 2025, then sank 148.22% in 2026.
- Over 3 years, Net Income towards Common Stockholders stood at -$2.8 million in 2024, then dropped by 16.29% to -$3.3 million in 2025, then jumped by 34.26% to -$2.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.2 million, -$3.3 million, and -$1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -849,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -849,000.00 |
| Mar 31, 2026 | -2.16 Mn |
| Dec 31, 2025 | -3.28 Mn |
| Sep 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -1.81 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | -2.82 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -4.03 Mn |
| Mar 31, 2024 | -3.23 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | -20.14 Mn |
| Jun 30, 2021 | -19.89 Mn |
| Mar 31, 2021 | -17.44 Mn |
| Dec 31, 2020 | -4.97 Mn |
| Sep 30, 2020 | -15.18 Mn |
| Jun 30, 2020 | -13.60 Mn |
| Mar 31, 2020 | -16.66 Mn |
| Dec 31, 2019 | -6.59 Mn |
| Sep 30, 2019 | -9.82 Mn |